【誉衡药业：三高管拟合计减持0.0639%公司股份】誉衡药业公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减持原因是个人资金需求，减持价格将按市场价格确定。

金融界2025-05-29

誉衡药业公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减持原因是个人资金需求，减持价格将按市场价格确定。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2539125763?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-29 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539125763","market":"hk","top_or_hot":-1,"title":"【誉衡药业：三高管拟合计减持0.0639%公司股份】誉衡药业公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减持原因是个人资金需求，减持价格将按市场价格确定。","media":"金融界","content":"<div>\n<p>誉衡药业公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减持原因是个人资金需求，减持价格将按市场价格确定。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/05/29194150747748.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【誉衡药业：三高管拟合计减持0.0639%公司股份】誉衡药业公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减持原因是个人资金需求，减持价格将按市场价格确定。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【誉衡药业：三高管拟合计减持0.0639%公司股份】誉衡药业公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减持原因是个人资金需求，减持价格将按市场价格确定。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-29 19:41 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/05/29194150747748.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>誉衡药业公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减持原因是个人资金需求，减持价格将按市场价格确定。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/05/29194150747748.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/05/29194150747748.shtml","article_id":"2539125763","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539125763","pubTimestamp":1748518890,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"誉衡药业公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减持原因是个人资金需求，减持价格将按市场价格确定。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0077":"质押式回购","BK0095":"互联网金融","BK0060":"抗癌","BK0239":"医药制造","002437":"誉衡药业","BK0028":"国家队","BK0188":"融资融券"},"translate_title":"[Yuheng Pharmaceutical: Three executives plan to reduce their holdings of 0.0639% of the company's shares in total] Yuheng Pharmaceutical announced that deputy general manager Li Runbao, deputy general manager Wang Xiaohang and director, deputy general manager and secretary of the board of directors Liu Yueyin plan to reduce their holdings of the company's shares through centralized bidding within three months after 15 trading days from the date of announcement. Li Runbao and Wang Xiaohang each plan to reduce their holdings by 587,500 shares, each accounting for 0.0262% of the company's total ","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002437":1},"content_text":"誉衡药业公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减持原因是个人资金需求，减持价格将按市场价格确定。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2539125763","isCrawlerRequest":true}